Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection

Simeprevir provides a new triple therapy treatment option, as well as the first ever 12-week interferon-free and ribavirin independent treatment regimen, in combination with sofosbuvir, for appropriate patients in Europe

Published
16 May 2014
From
Reuters
To curb hepatitis C, test and treat inmates

The nation's oversized prison population provides an opportunity to battle the US hepatitis C epidemic because inmates have a high prevalence of infection and are readily reachable for testing and treatment, argue authors of a new article in the New England Journal of Medicine. One in six inmates is infected and one in three infected Americans ends up locked up for at least a little time in their lives.

Published
15 May 2014
From
Eurekalert Inf Dis
Even moderate drinking increases risk of advanced liver fibrosis for people with HIV and HCV co-infection

Even moderate alcohol consumption is associated with an increased risk of advanced liver fibrosis for people living with HIV and hepatitis C virus (HCV) co-infection, investigators from the

Published
12 May 2014
By
Michael Carter
AbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C

Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date. European Medicines Agency has granted AbbVie's request for accelerated assessment.

Published
08 May 2014
From
AbbVie press release
Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation

An interferon-free combination of sofosbuvir (Sovaldi) plus ribavirin taken for up to 24 weeks led to sustained virological response in 70% of liver transplant recipients with hepatitis C

Published
08 May 2014
By
Liz Highleyman
ITPCru report: Access to drugs for treating hepatitis C in Russia in 2013

The report contains data about hepatitis C drug prices in Russia, the number of patients that can potentially be treated, market volumes, market distribution, statistics on the prevalence and incidence of hepatitis C, information about advocacy actions undertaken, recommendations to decision-makers.

Published
08 May 2014
From
EATG
Janssen submits US FDA new drug application for simeprevir / sofosbuvir combination use

Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc. This regulatory submission is for the treatment of genotype 1 chronic hepatitis C (HCV) in adult treatment-naive patients with advanced fibrosis and null responders with all stages of liver fibrosis.

Published
08 May 2014
From
Janssen press release
UNITAID approves grants of $160 million, for hepatitis C, MDR-TB and malaria drugs

Breakthrough new medicines for hepatitis C and drug-resistant TB and largest-yet global programme for seasonal malaria chemoprevention to be made available for low- and middle-income countries as part of $160 million of new grants funded by UNITAID

Published
07 May 2014
From
UNITAID
UK - 'Eradicating hepatitis C is a realistic aim'

New highly effective drugs have created the potential for the eradication of hepatitis C, says Stephen Ryder and John Dillon, but the NHS must clear several hurdles to reach this goal.

Published
06 May 2014
From
Health Service Journal
Sustained response to treatment reduces fatigue in hepatitis C patients

Curative treatment that eliminates hepatitis C virus (HCV) from the body can reduce central fatigue, one of the most concerning symptoms associated with chronic hepatitis C, according

Published
06 May 2014
By
Liz Highleyman

Filter by country